UPTRAVI TABLET

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

SELEXIPAG

Fáanlegur frá:

JANSSEN INC

ATC númer:

B01AC27

INN (Alþjóðlegt nafn):

SELEXIPAG

Skammtar:

400MCG

Lyfjaform:

TABLET

Samsetning:

SELEXIPAG 400MCG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

60

Gerð lyfseðils:

Prescription

Lækningarsvæði:

VASODILATING AGENTS

Vörulýsing:

Active ingredient group (AIG) number: 0157750002; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2016-01-20

Vara einkenni

_~db5_O86888dc76b8743cbbde36e6d10b4eb1b.docx _
_EDMS-RIM-516055 v12.0 _
_Page 1 of 37 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
UPTRAVI
®
Selexipag Film-coated tablets
200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, and
1600 mcg
Professed standard
Prostacyclin (PGI
2
) receptor (IP receptor) agonist
Janssen Inc
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.com/canada
Date of Initial Authorization:
January 20, 2016
Date of Revision:
April 21, 2022
Submission Control Number: 258347
© 2022 Janssen Inc.
All trademarks used under licence.
_~db5_O86888dc76b8743cbbde36e6d10b4eb1b.docx _
_EDMS-RIM-516055 v12.0 _
_Page 2 of 37 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment, Dosage adjustment with co-administration of moderate
CYP2C8
inhibitors
06/2020
7 WARNINGS AND PRECAUTIONS
11/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics............................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................
4
4.2
Recommended Dose and Dosage Adjustment
.................................................